The ANNOUNCE trial, a global, randomized, placebo-controlled Phase III study of LARTRUVO in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin as compared to doxorubicin alone, a standard of care treatment.
Products affected
LARTRUVO (olaratumab) solution for injection, 10 mg/mL (19 mL and 50 mL vials), intravenous infusion.
Background information
In Canada, LARTRUVO has been
issued marketing authorization with conditions based on the promising evidence of an overall survival benefit demonstrated in a Phase II study. Continued authorization was contingent on verification of clinical benefit in a confirmatory Phase III study. LARTRUVO has been authorized, in combination with doxorubicin, for the treatment of adult patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and for whom treatment with an anthracycline-containing regimen is appropriate. In Canada, as of January 28, 2019, there are approximately 180 patients undergoing treatment with LARTRUVO.
The ANNOUNCE trial, a global, randomized, placebo-controlled Phase III study of LARTRUVO in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin as compared to doxorubicin, a standard of care treatment.
Specifically, the study did not meet the primary endpoints to prolong survival in the overall population (hazard ratio [HR]: 1.05; Median 20.4 vs. 19.7 months for LARTRUVO + doxorubicin and doxorubicin, respectively) or in the leiomyosarcoma (LMS) sub-population (HR: 0.95; Median 21.6 vs. 21.9 months for LARTRUVO + doxorubicin and doxorubicin, respectively). There was also a shortening in progression free survival in the LARTRUVO plus doxorubicin arm (median 5.4 months for Lartruvo plus doxorubicin versus 6.8 months for doxorubicin), which was one of the secondary objectives of the study. Based on the information available so far, no new safety concerns were identified during the study.
Lilly is in the process of reviewing the full results of the ANNOUNCE study and is working with global regulators to determine the appropriate next steps for LARTRUVO.